Article thumbnail

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

By Fiona M. Blows, Kristy E. Driver, Marjanka K. Schmidt, Annegien Broeks, Flora E. van Leeuwen, Jelle Wesseling, Maggie C. Cheang, Karen Gelmon, Torsten O. Nielsen, Carl Blomqvist, Päivi Heikkilä, Tuomas Heikkinen, Heli Nevanlinna, Lars A. Akslen, Louis R. Bégin, William D. Foulkes, Fergus J. Couch, Xianshu Wang, Vicky Cafourek, Janet E. Olson, Laura Baglietto, Graham G. Giles, Gianluca Severi, Catriona A. McLean, Melissa C. Southey, Emad Rakha, Andrew R. Green, Ian O. Ellis, Mark E. Sherman, Jolanta Lissowska, William F. Anderson, Angela Cox, Simon S. Cross, Malcolm W. R. Reed, Elena Provenzano, Sarah-Jane Dawson, Alison M. Dunning, Manjeet Humphreys, Douglas F. Easton, Montserrat García-Closas, Carlos Caldas, Paul D. Pharoah and David Huntsman


Paul Pharoah and colleagues evaluate the prognostic significance of immunohistochemical subtype classification in more than 10,000 breast cancer cases with early disease, and examine the influence of a patient's survival time on the prediction of future survival

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.
  2. (2002). A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer.
  3. (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
  4. (2004). Association of a common variant of the CASP8 gene with reduced risk of breast cancer.
  5. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
  6. (2007). Basal-like phenotype is not associated with patient survival in estrogenreceptor-negative breast cancers.
  7. (2006). Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.
  8. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
  9. (2007). Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
  10. (2007). Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
  11. (2006). Cancer Association Consortium
  12. (2005). Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
  13. (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
  14. (2006). Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
  15. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
  16. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
  17. (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
  18. (2005). Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
  19. (2003). Molecular classification of breast carcinomas using tissue microarrays.
  20. (2007). Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis.
  21. (2000). Molecular portraits of human breast tumours.
  22. (2008). NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
  23. Please access these Web sites via the online version of this summary at
  24. (2006). Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and metaanalyses.
  25. (2000). Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
  26. (2010). PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.
  27. (2009). Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?
  28. (2008). Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort.
  29. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
  30. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets.
  31. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
  32. (1995). Screening for breast cancer, time to think - and stop?
  33. (2010). Survival by IHC Subtype PLoS Medicine | 11
  34. (2002). The Melbourne Collaborative Cohort Study.
  35. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
  36. (2007). Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.